Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | GMNN | O75496 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626223 | 1.00 | MAPK1 (0.47) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL725613 | 1.00 | MAPK1 (0.47) | MAPK1MAPTMEN1GMNNLMNA | |
| Hydrochloric Acid SCHEMBL17241611 | 0.98 | MAPK1 (0.48) | MAPK1MAPTMEN1GMNNLMNA | |
| Hydrochloric Acid SCHEMBL1773167 | 0.98 | MAPK1 (0.48) | MAPK1MAPTMEN1GMNNLMNA | |
| SCHEMBL29077348 | 0.91 | SLC6A5 (0.52) | MAPTMEN1GMNNLMNAKMT2A | |
| SCHEMBL533830 | 0.91 | SLC6A5 (0.52) | MAPTMEN1GMNNLMNAKMT2A | |
| SCHEMBL533829 | 0.91 | SLC6A5 (0.52) | MAPTMEN1GMNNLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL20258167 | 0.90 | SLC6A5 (0.51) | MAPTMEN1GMNNLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL1773161 | 0.90 | SLC6A5 (0.51) | MAPTMEN1GMNNLMNAKMT2A | |
| Hydrochloric Acid SCHEMBL28566602 | 0.90 | SLC6A5 (0.51) | MAPTMEN1GMNNLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024144348-A1 | VACCINE COMPOSITION COMPRISING IONIC COMPLEX OF CATIONIC MOLECULAR TRANSPORTER AND MRNA | 주식회사 바이오파마 | 2024-07-04 | — | — | WO | claimed |
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | EYEGENE INC. (KR) | 2024-05-23 | — | — | US | claimed |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | EYEGENE INC. (KR) | 2024-05-09 | — | — | US | claimed |
| EP-4365168-A1 | POLYOL-MODIFIED LIPID COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | Jenkem Technology Co., Ltd. (Tianjin) (CN) | 2024-05-08 | — | — | EP | claimed |
| EP-4356933-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | Eyegene, Inc. (KR) | 2024-04-24 | — | — | EP | claimed |
| US-20240115513-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| WO-2024054020-A1 | COMPOSITION FOR DELIVERING MODIFIED NUCLEIC ACID-CONTAINING MRNA | 아이진 주식회사 | 2024-03-14 | — | — | WO | claimed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | claimed |
| EP-4306132-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPARATION METHOD THEREFOR | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| EP-4306126-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | Eyegene Inc. (KR) | 2024-01-17 | — | — | EP | claimed |
| EP-2167124-B1 | THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT | STATENS SERUMINSTITUT (DK) | 2012-08-01 | — | — | EP | claimed |
| US-20110287087-A1 | MODIFIED CATIONIC LIPOSOME ADJUVANS | STATENS SERUM INSTITUT (DK) | 2011-11-24 | — | — | US | claimed |
| WO-2011098578-A2 | LIPOSOME SYSTEM FOR OCULAR ADMINISTRATION | BIONEER A/S (DK) | 2011-08-18 | — | — | WO | claimed |
| US-20080118489-A1 | Charge-Modified Lysozyme Antimicrobial Compositions, Surfactants, and Methods for Infections and Cystic Fibrosis | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-22 | — | — | US | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-6562371-B1 | Basic compound that becomes charged at physiological pH and lipid drug delivery system; blood stability | TERUMO KABUSHIKI KAISHA (JP) | 2003-05-13 | — | — | US | claimed |
| US-20020102297-A1 | Macromolecule-lipid complexes and methods for making and using | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-08-01 | — | — | US | claimed |
| EP-1225916-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING | University Technology Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001032218-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING | UNIVERSITY TECHNOLOGY CORPORATION (US) | 2001-05-10 | — | — | WO | claimed |
| WO-2000000033-A1 | MACROMOLECULE-LIPID COMPLEXES AND METHODS FOR MAKING AND USING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165222-A1 | VACCINE COMPOSITION FOR PREVENTING SARS-COV-2 | ACE2, SARS1, RBM22 | MAPK1 4479/4885MAPT 950/4885MEN1 4007/4885 |
| US-20240148897-A1 | COMPOSITION FOR IN VIVO DELIVERY OF RNA AND PREPERATION METHOD THEREFOR | RTCB, RRP1B, PRPF6 | MAPK1 4733/4885MAPT 3423/4885MEN1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.